⚠️ JAN 12 – FEB 6 CYBERATTACK: ALL ORDERS REFUNDED • DO NOT PURCHASE UNTIL FURTHER NOTICE • CONTACT support@anubis.estate FOR REFUND STATUS
Post-market surveillanceMitochondrial Peptide

Compound 61473

Formula Pending

Molecular Mass
N/A
CAS Registry
AUTO-061473
Risk Class
MODERATE
Last Audit
Feb 26, 2108

Research Abstract

Mitochondrial Peptide candidate engineered for oncology adjuvant initiatives with automated dossier coverage.

Compound 61473 is a mitochondrial peptide asset inside mitochondrial peptide innovation track initiatives, optimized for oncology adjuvant and inflammation control.

The dossier currently sits in post-market surveillance with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.

Supply records cite CAS AUTO-061473 with updates logged 2108-02-26.

Acquisition Protocol

Authorized research personnel may request deployment of this compound for laboratory analysis.

Primary Vectors

Oncology adjuvantInflammation control

Nomenclature

CX-61473Mitochondrial Peptide Program 61473

Reference Material

  1. [1] Anubis Compound Registry • CAS AUTO-061473
  2. [2] Operations Pulse • Mitochondrial Peptide innovation track
  3. [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61473